![Javier Szwarcberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Javier Szwarcberg
Verkställande Direktör på
SPRUCE BIOSCIENCES, INC.
Förmögenhet: 825 334 $ per 2026-07-31
Profil
Javier Szwarcberg is Chief Executive Officer & Executive Director at Spruce Biosciences, Inc. since 2022.
Formerly, Dr. Szwarcberg was Group VP, Head-Product & Portfolio Development at BioMarin Pharmaceutical, Inc. from 2020 to 2022, Senior VP-Program & Portfolio Management at Ultragenyx Pharmaceutical, Inc. from 2017 to 2020, and Vice President-Clinical & Business Development at Horizon Therapeutics Ltd. (Ireland) from 2016 to 2017.
Education includes a doctorate from Universidad de Buenos Aires and graduate studies at Harvard T.H.
Chan School of Public Health.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SPRUCE BIOSCIENCES, INC. 0,67 % | 2026-06-30 | 19 270 ( 0,67 % ) | 825 334 $ | 2026-07-31 |
Aktiva positioner av Javier Szwarcberg
| Företag | Position | Start |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Verkställande Direktör | 2022-01-03 |
Tidigare kända positioner av Javier Szwarcberg
| Företag | Position | Slut |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Företagsledare/Principal | 2022-01-01 |
| ULTRAGENYX PHARMACEUTICAL INC. | Företagsledare/Principal | 2020-02-01 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Teknisk/Vetenskaplig/F&U Direktör | 2017-10-01 |
Javier Szwarcbergs utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
66
Första gradens relationer
6
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 6 |
|---|---|
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Horizon Therapeutics Ltd. (Ireland)
 Horizon Therapeutics Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Discovers, develops and manufactures pharmaceuticals for autoimmune & inflammatory diseases | Health Technology |
Universidad de Buenos Aires
 Universidad de Buenos Aires Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders | Health Technology |
